Subscribe
scotus-istock-482156434-1
renaschild / iStockphoto.com
18 May 2021BiotechnologyMuireann Bolger

SCOTUS declines patents review on Enbrel drug

A  Novartis unit,  Sandoz, has failed to persuade the  US Supreme Court to review two Amgen-owned patents on the rheumatoid arthritis drug  Enbrel (etanercept), preventing the roll-out of any copies in the US until 2029.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sandoz fails in Enbrel patent challenge, but Fed Circuit split
2 July 2020   Amgen has won a key patent victory over Sandoz in a dispute over biologic Enbrel.
Americas
Amgen urges Fed Circuit to deny Sandoz petition
27 August 2020   Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Sandoz fails in Enbrel patent challenge, but Fed Circuit split
2 July 2020   Amgen has won a key patent victory over Sandoz in a dispute over biologic Enbrel.
Americas
Amgen urges Fed Circuit to deny Sandoz petition
27 August 2020   Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.

More on this story

Americas
Sandoz fails in Enbrel patent challenge, but Fed Circuit split
2 July 2020   Amgen has won a key patent victory over Sandoz in a dispute over biologic Enbrel.
Americas
Amgen urges Fed Circuit to deny Sandoz petition
27 August 2020   Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug